Human monocyte recognition of adenosine-based cyclic dinucleotides unveils the A2a Gαs protein-coupled receptor tonic inhibition of mitochondrially induced cell death

Molecular and Cellular Biology

Volumn 35, Issue 2, 2015, Pages 479-495

  Tosolini, Marie ^a,b,c,d,e   Pont, Frédéric ^a,b   Bétous, Delphine ^a,b,c,d,e   Ravet, Emmanuel ^f   Ligat, Laetitia ^a,b   Lopez, Frédéric ^a,b   Poupot, Mary ^a,b,c,d,e   Poirot, Marc ^a,b   Pérouzel, Éric ^f   Tiraby, Gérard ^f   Verhoeyen, Els ^g,h   Fournié, Jean Jacques ^a,b,c,d,e  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CHU PURPAN   (France)

^d Laboratoire d Excellence TOUCAN   (France)

^e Institut Carnot CALYM   (France)

^f Zone industrielle de Montaudran   (France)

^g CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^h CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE PHOSPHATE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DINUCLEOTIDE; G PROTEIN COUPLED RECEPTOR; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PROTEIN P53; ADENOSINE A2A RECEPTOR; CYCLIC AMP; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOSOL; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAMMAL CELL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MONOCYTE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL DEATH; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

MAMMALIA; MUS; PROTOZOA;

ADENOSINE; ANIMALS; CELL DEATH; CYCLIC AMP; HUMANS; MICE, INBRED C57BL; MITOCHONDRIA; MONOCYTES; PHOSPHORYLATION; RECEPTOR, ADENOSINE A2A; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84919626408     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01204-14     Document Type: Article

References (52)

1. Pesavento C, Hengge R. 2009. Bacterial nucleotide-based second messengers. Curr Opin Microbiol 12:170-176. http://dx.doi.org/10.1016/j.mib.2009.01.007.
2. Chen Z-H, Schaap P. 2012. The prokaryote messenger c-di-GMP triggers stalk cell differentiation in Dictyostelium. Nature 488:680-683. http://dx.doi.org/10.1038/nature11313.
3. Gao D, Wu J, Wu Y-T, Du F, Aroh C, Yan N, Sun L, Chen ZJ. 2013. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341:903-906. http://dx.doi.org/10.1126/science.1240933.
4. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ. 2013. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339:826-830. http://dx.doi.org/10.1126/science.1229963.
5. Sun L, Wu J, Du F, Chen X, Chen ZJ. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339:786-791. http://dx.doi.org/10.1126/science.1232458.
6. Zhou R, Yazdi AS, Menu P, Tschopp J. 2011. A role for mitochondria in NLRP3 inflammasome activation. Nature 469:221-225. http://dx.doi.org/10.1038/nature09663.
7. Pont F, Familiades J, Dejean S, Fruchon S, Cendron D, Poupot M, Poupot R, L'faqihi-Olive F, Prade N, Ycart B, Fournie J-J. 2012. The gene expression profile of phosphoantigen-specific human T lymphocytes is a blend of T-cell and NK-cell signatures. Eur J Immunol 42:228-240. http://dx.doi.org/10.1002/eji.201141870.
8. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L. 2009. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459:717-721. http://dx.doi.org/10.1038/nature07968.
9. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S. 2009. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:899-911. http://dx.doi.org/10.1016/j.immuni.2009.03.019.
10. Andersson A, Pedén Olofsson T, Fioretos T. 2010. Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies. BMC Med Genomics 3:6. http://dx.doi.org/10.1186/1755-8794-3-6.
11. Bennett KA, Tehan B, Lebon G, Tate CG, Weir M, Marshall FH, Langmead CJ. 2013. Pharmacology and structure of isolated conformations of the adenosine A2A receptor define ligand efficacy. Mol Pharmacol 83:949-958. http://dx.doi.org/10.1124/mol.112.084509.
12. Lebon G, Tate CG. 2011. Structure of the adenosine-bound conformation of the human adenosine A(2A) receptor. Med Sci (Paris) 27:926-928. http://dx.doi.org/10.1051/medsci/20112711004.
13. Grosdidier A, Zoete V, Michielin O. 2011. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 39:W270-W277. http://dx.doi.org/10.1093/nar/gkr366.
14. Van Damme T, Zhang Y, Lynen F, Sandra P. 2012. Determination of cyclic guanosine-and cyclic adenosine monophosphate (cGMP and cAMP) in human plasma and animal tissues by solid phase extraction on silica and liquid chromatography-triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 909:14-21. http://dx.doi.org/10.1016/j.jchromb.2012.10.002.
15. Petronilli V, Miotto G, Canton M, Brini M, Colonna R, Bernardi P, Lisa FD. 1999. Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J 76:725-734. http://dx.doi.org/10.1016/S0006-3495(99)77239-5.
16. Witte CE, Whiteley AT, Burke TP, Sauer J-D, Portnoy DA, Woodward JJ. 2013. Cyclic di-AMP is critical for Listeria monocytogenes growth, cell wall homeostasis, and establishment of infection. mBio 4(3):e00282-13. http://dx.doi.org/10.1128/mBio.00282-13.
17. Jacobson KA, Gao Z-G. 2006. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264. http://dx.doi.org/10.1038/nrd1983.
18. Brand F, Klutz AM, Jacobson KA, Fredholm BB, Schulte G. 2008. Adenosine A2a receptor dynamics studied with the novel fluorescent agonist Alexa488-APEC. Eur J Pharmacol 590:36-42. http://dx.doi.org/10.1016/j.ejphar.2008.05.036.
19. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AGW, Tate CG. 2011. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474:521-525. http://dx.doi.org/10.1038/nature10136.
20. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. 2013. Molecular signatures of G-protein-coupled receptors. Nature 494:185-194. http://dx.doi.org/10.1038/nature11896.
21. Schulte G, Fredholm BB. 2000. Human adenosine A1, A2A, A2B, and A3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol 58:477-482.
22. Inoue A, Ishiguro J, Kitamura H, Arima N, Okutani M, Shuto A, Higashiyama S, Ohwada T, Arai H, Makide K, Aoki J. 2012. TGF alpha shedding assay: an accurate and versatile method for detecting GPCR activation. Nat Methods 9:1021-1029. http://dx.doi.org/10.1038/nmeth.2172.
23. Konno H, Konno K, Barber GN. 2013. Cyclic dinucleotides trigger ULK1(ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell 155:688-698. http://dx.doi.org/10.1016/j.cell.2013.09.049.
24. Zhang F, Hu Y, Huang P, Toleman CA, Paterson AJ, Kudlow JE. 2007. Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J Biol Chem 282:22460-22471. http://dx.doi.org/10.1074/jbc.M702439200.
25. Safa M, Kazemi A, Zand H, Azarkeivan A, Zaker F, Hayat P. 2010. Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues. Apoptosis 15:196-203. http://dx.doi.org/10.1007/s10495-009-0417-8.
26. Safa M, Kazemi A, Zaker F, Razmkhah F. 2011. Cyclic AMP-induced p53 destabilization is independent of EPAC in pre-B acute lymphoblastic leukemia cells in vitro. J Recept Signal Transduct Res 31:256-263. http://dx.doi.org/10.3109/10799893.2011.578140.
27. Pediaditakis P, Kim J-S, He L, Zhang X, Graves LM, Lemasters JJ. 2010. Inhibition of the mitochondrial permeability transition by protein kinase A in rat liver mitochondria and hepatocytes. Biochem J 431:411-421. http://dx.doi.org/10.1042/BJ20091741.
28. Crompton M, Ellinger H, Costi A. 1988. Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 255:357-360.
29. Broekemeier K, Dempsey M, Pfeiffer D. 1989. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 264:7826-7830.
30. Ito M, Kobayashi K, Nakahata T. 2008. NOD/Shi-scid IL2rnull (NOG) mice more appropriate for humanized mouse models. Curr Top Microbiol Immunol 324:53-76. http://dx.doi.org/10.1007/978-3-540-75647-7_3.
31. Shima H, Takubo K, Iwasaki H, Yoshihara H, Gomei Y, Hosokawa K, Arai F, Takahashi T, Suda T. 2009. Reconstitution activity of hypoxic cultured human cord blood CD34-positive cells in NOG mice. Biochem Biophys Res Commun 378:467-472. http://dx.doi.org/10.1016/j.bbrc.2008.11.056.
32. Cai S, Wang H, Bailey B, Hartwell JR, Silver JM, Juliar BE, Sinn AL, Baluyut AR, Pollok KE. 2011. Differential secondary reconstitution of in vivo-selected human SCID-repopulating cells in NOD/SCID versus NOD/SCID/g chain null mice. Bone Marrow Res 2011:252953. http://dx.doi.org/10.1155/2011/252953.
33. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y, Hirai H. 1992. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79:2378-2383.
34. Schmidt-Weber C, Rittig M, Buchner E, Hauser I, Schmidt I, Palombo-Kinne E, Emmrich F, Kinne RW. 1996. Apoptotic cell death in activated monocytes following incorporation of clodronate-liposomes. J Leukoc Biol 60:230-244.
35. Crossman D, Whyte M. 1993. Adenosine-A2 receptor stimulation of human neutrophils inhibits programmed cell-death (apoptosis). Circulation 88:545-545.
36. Boucher M, Wann B, Kaloustian S, Cardinal R, Godbout R, Rousseau G. 2006. Reduction of apoptosis in the amygdala by an A2A adenosine receptor agonist following myocardial infarction. Apoptosis 11:1067-1074. http://dx.doi.org/10.1007/s10495-006-6313-6.
37. Kalda A, Yu L, Oztas E, Chen J-F. 2006. Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 248:9-15. http://dx.doi.org/10.1016/j.jns.2006.05.003.
38. Yu L, Shen H-Y, Coelho J E, Arajo IM, Huang Q-Y, Day Y-J, Rebola N, Canas PM, Rapp EK, Ferrara J, Taylor D, Mller CE, Linden J, Cunha RA, Chen J-F. 2008. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 63:338-346. http://dx.doi.org/10.1002/ana.21313.
39. Mayne M, Fotheringham J, Yan H-J, Power C, Del Bigio MR, Peeling J, Geiger JD. 2001. Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann Neurol 49:727-735. http://dx.doi.org/10.1002/ana.1010.
40. Cassada DC, Tribble CG, Long SM, Kaza AK, Linden J, Rieger JM, Rosin D, Kron IL, Kern JA. 2002. Adenosine A2A agonist reduces paralysis after spinal cord ischemia: correlation with A2A receptor expression on motor neurons. Ann Thorac Surg 74:846-850. http://dx.doi.org/10.1016/S0003-4975(02)03793-1.
41. Chen J-F, Xu K, Petzer JP, Staal R, Xu Y-H, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N, Jr, Schwarzschild MA. 2001. Neuroprotection by caffeine and A (2A) adenosine receptor inactivation in a model of Parkinsons disease. J Neurosci 21:RC143.
42. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung K-H, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR. 2000. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674-2679. http://dx.doi.org/10.1001/jama.283.20.2674.
43. Lin J, Yueh K. 2013. Genetic polymorphism of adenosine A2a receptor is associated with the development of Parkinson's disease and of L-dopainduced hyperkinesia. Mov Disord 28:S39.
44. Chen W, Wang H, Wei H, Gu S, Wei H. 2013. Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's disease: a meta-analysis. J Neurol Sci 324:21-28. http://dx.doi.org/10.1016/j.jns.2012.08.030.
45. Mehlen P, Bredesen DE. 2000. Dependence receptors: links between apoptosis, nervous system development and control of tumorigenesis. Bull Cancer 87:537-541. (In French.)
46. Mehlen P. 2005. The dependence receptor notion: another way to see death. Cell Death Differ 12:1003. http://dx.doi.org/10.1038/sj.cdd.4401708.
47. Tamura K, Kanno T, Fujita Y, Gotoh A, Nakano T, Nishizaki T. 2012. A2a adenosine receptor mediates HepG2 cell apoptosis by downregulating Bcl-XL expression and upregulating bid expression. J Cell Biochem 113:1766-1775. http://dx.doi.org/10.1002/jcb.24048.
48. Long JS, Crighton D, O'Prey J Mackay G, Zheng L, Palmer TM, Gottlieb E, Ryan KM. 2013. Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53. Mol Cell 50:394-406. http://dx.doi.org/10.1016/j.molcel.2013.03.016.
49. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM. 2012. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149:1536-1548. http://dx.doi.org/10.1016/j.cell.2012.05.014.
50. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K. 2011. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 10:221-229. http://dx.doi.org/10.1016/S1474-4422(11)70012-6.
51. Schapira AHV, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Novre NL, Obeso J A, Schwarzschild MA, Spampinato U, Davidai G. 2006. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5:845-854. http://dx.doi.org/10.1038/nrd2087.
52. Desmet CJ, Gallenne T, Prieur A, Reyal F, Visser NL, Wittner BS, Smit MA, Geiger TR, Laoukili J, Iskit S, Rodenko B, Zwart W, Evers B, Horlings H, Ajouaou A, Zevenhoven J, van Vliet M, Ramaswamy S, Wessels LFA, Peeper DS. 2013. Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A 110:5139-5144. http://dx.doi.org/10.1073/pnas.1222085110.